Log in to search using one of your social media accounts:

This page shows you the latest news items in this category.

Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA Based on EINSTEIN CHOICE Data, Which Showed Superiority with XARELTO ® (rivaroxaban) Versus Aspirin in Reducing Risk of Recurrent Venous Thromboembolism (VTE), with Low Rates of Major Bleeding Across Groups
Filing seeks update to prescribing information to include additional dosage of XARELTO ® to reduce risk of recurrent VTE (Source: Johnson and Johnson)
Source: Johnson and Johnson - April 28, 2017 Category: Pharmaceuticals Source Type: news

Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism (for specialized target groups only)
If approved, rivaroxaban 10 mg once daily will provide an additional treatment option alongside the already approved rivaroxaban 20 mg once-daily dose / Risk of recurrent thrombosis is up to 10% in the first year if anticoagulation therapy is stopped / Application to FDA supported by data from the EINSTEIN CHOICE study (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2017 Category: Pharmaceuticals Source Type: news

Novel ultrasound device dev Sonavex raises $3m
John Hopkins spin-out Sonavex said today it raised $3 million in financing, including a $2.2 million closed Series A round to support its novel ultrasound technology. The round was led by Grey Sky Venture Partners and joined by CRCM Venture Capital, Tedco, the Abell Foundation and individual investors, the Baltimore, Md.-based company said. The round was also expanded by $1.3 million “following increased demand from investors,” Sonavex added. “This represents an exciting time for the company. Our traction has enabled Sonavex to not only raise capital to accomplish critical milestones, but also attract es...
Source: Mass Device - April 24, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Ultrasound sonavex Source Type: news

Sleep Studies and VTEs Headline Hospitalists Meeting Sleep Studies and VTEs Headline Hospitalists Meeting
Curbing interruptions to patient ' s sleep and a rare look into hospital-associated venous thromboembolism (VTEs) will be among the hot topics at the upcoming Society of Hospital Medicine meeting.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2017 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Abbott issues select recall for NC coronary dilation & balloon caths
Abbott (NYSE:ABT) has issued an urgent field safety notice looking to recall select coronary dilation and balloon catheters over issues with inflating and deflating the balloons. The company said it is recalling specific lots of the NC Trek RX coronary dilation catheter, the NC Traveler RX coronary dilation catheter and the NC Tenku RX PTCA balloon catheter over issues with removing the protective balloon sheath which can result in issues inflating or deflating the balloon. Risks associated with inflation and deflation issues include air embolism, thrombosis, myocardial infarction and may require additional intervention. ...
Source: Mass Device - April 21, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Catheters Recalls Abbott Source Type: news

Focused issue on vascular disease in women available now
(SAGE) Vascular disease is a leading cause of morbidity and death worldwide. There are important sex-related differences in risk factors, clinical manifestations, and therapeutic outcomes in peripheral vascular diseases, including peripheral artery disease (PAD), venous thromboembolism (VTE), and aortic disease. In addition, some vascular conditions predominantly affect women. With this in mind, Vascular Medicine, the official journal of the Society for Vascular Medicine, dedicated its April 2017 issue to the topic of Vascular Disease in Women. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 21, 2017 Category: Global & Universal Source Type: news

Even Short-term Oral Steroids Carry Serious Risk Even Short-term Oral Steroids Carry Serious Risk
A large, population-based study found a significantly higher rate of acute adverse events such as sepsis, venous thromboembolism, and fracture, even after a low-dose, short-term steroid treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Medtronic Signs Definitive Agreement to Divest a Portion of Its Patient Monitoring and Recovery Division to Cardinal Health for $6.1 Billion
DUBLIN - April 18, 2017 -- (Healthcare Sales & Marketing Network) -- Medtronic plc (NYSE: MDT) today announced that it has entered into a definitive agreement with Cardinal Health Inc. (NYSE: CAH) to sell its Patient Care, Deep Vein Thrombosis, and Nutriti... Devices, Acquisitions Medtronic, Cardinal Health, Deep Vein Thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 18, 2017 Category: Pharmaceuticals Source Type: news

Cardinal Health buying medical supplies business from Medtronic for $6.1 billion
Cardinal Health Inc. is buying several medical product lines from Medtronic for $6.1 billion in cash. In the deal with the medical-device giant, Dublin-based Cardinal (NYSE:CAH) has agreed to buy Medtronic's patient care, deep vein thrombosis and nutritional insufficiency lines. The company said the lines include 23 product categories and several well-established brands used in nearly every U.S. hospital, including Curity, Kendall, Dover, Argyle and Kangaroo. The deal had been suspected; Medtronic… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 18, 2017 Category: Pharmaceuticals Authors: Doug Buchanan Source Type: news

Cardinal Health buying medical supplies business from Medtronic for $6.1 billion
Cardinal Health Inc. is buying several medical product lines from Medtronic for $6.1 billion in cash. In the deal with the medical-device giant, Dublin-based Cardinal (NYSE:CAH) has agreed to buy Medtronic's patient care, deep vein thrombosis and nutritional insufficiency lines. The company said the lines include 23 product categories and several well-established brands used in nearly every U.S. hospital, including Curity, Kendall, Dover, Argyle and Kangaroo. "We are thrilled about today's announcement,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 18, 2017 Category: Pharmaceuticals Authors: Doug Buchanan Source Type: news

UPDATE: Medtronic deals patient monitoring & recovery biz to Cardinal Health for $6B
Medtronic (NYSE:MDT) said today that it agreed to deal a portion of its patient monitoring & recovery business to Cardinal Health (NYSE:CAH) for $6.1 billion in cash, confirming months of speculation that the world’s largest medical device maker was looking to slim down. Rumors that the Fridley, Minn.-based company wanted to divest the supplies business, gained as part of its $50 billion Covidien acquisition, 1st emerged in early February. In March several companies were said to be interested, Dublin, Ohio.-based Cardinal Health among them; earlier this month Cardinal was said to be closing in on a deal. The me...
Source: Mass Device - April 18, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Wall Street Beat Cardinal Health Medtronic Source Type: news

Thrombosis, Bleeding Risks Vary Across Urological Cancer Surgeries Thrombosis, Bleeding Risks Vary Across Urological Cancer Surgeries
The procedure-specific risks of venous thromboembolism (VTE) and bleeding vary widely across different urological cancer surgeries, according to a systematic review.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 17, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Housecall: Planning ahead for safe travels
THIS WEEK'S TOP STORIES Deep vein thrombosis: Prevention If vacation plans are in your future, plan ahead to stay safe on the way. Sitting for long stretches in a car or plane raises your risk for blood clots. Here's how to avoid them. Mediterranean diet: A heart-healthy eating plan If you're looking for a heart-healthy [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 17, 2017 Category: Databases & Libraries Source Type: news

Short-Term Use of Oral Corticosteroids Tied to Sepsis, VTE, and Fracture (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Short-term use of oral corticosteroids is associated with increased risks for sepsis, venous thromboembolism (VTE), and fracture, according … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 14, 2017 Category: Primary Care Source Type: news

Cook Medical recalls select Bush ureteral illuminating caths
Cook Medical this week released information on a select voluntary recall of its Bush DL and Bush SL ureteral illuminating catheter sets over issues with overheating. The Bloomington, Ind.-based company said it has received an increased number of reports of the proximal black component that connects to the distal transparent component overheating and melting, which could potentially cause burns. Cook Medical clarified that it has received no reports of any overheating along the transparent component of the catheter which comes into contact with the patients’ urethra, bladder and ureter. The recall affects Bush DL cath s...
Source: Mass Device - April 12, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Catheters Recalls Urology Cook Medical Source Type: news

Inari Medical wins FDA nod for ClotTriever peripheral thrombectomy device
Inari Medical said today that the FDA granted pre-market approval in February for its ClotTriever thrombectomy device Feb. 16 and already has the 1st commercial procedure under its belt. Irvine, Calif.-based Inari said the ClotTriever device is designed to remove blood clots from large vessels in the peripheral vasculature. The company also makes the FlowTriever device, which is designed to retrieve pulmonary embolisms. “The ClotTriever system is the 2nd product offering in Inari’s product portfolio,” CEO Bill Hoffman said in prepared remarks.  “The ClotTriever is currently available for treat...
Source: Mass Device - April 10, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Wall Street Beat Inari Medical Peripheral Artery Disease Source Type: news

Dissolving Stent Pulled in Europe; TAVR Thrombosis Checkups; Firefighters ' Hearts
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 7, 2017 Category: Urology & Nephrology Source Type: news

Implications of Subclinical Leaflet Thrombosis in TAVR/SAVR Implications of Subclinical Leaflet Thrombosis in TAVR/SAVR
Dr Makkar provides more insights from the SAVORY and RESOLVE registries on the phenomenon of bioprosthetic valve leaflet thrombosis seen on 4D CT.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 5, 2017 Category: Cardiology Tags: Cardiology Expert Interview Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 4, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Medical Technology Venture Partners raises $20m toward $50m fund Medical Technology Venture Partners reported raising $20 million for its maiden $50 million fund. The San Francisco-based VC shop said in a regulatory filing that...
Source: Mass Device - April 4, 2017 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Cook Medical warns of thrombus risk with Zenith Alpha stent graft
Cook Medical this month released an urgent safety notice warning of clot risks associated with its Zenith Alpha thoracic endovascular graft when used to treat blunt thoracic aortic injuries. The company warned of a 25% observed rate of thrombus within the graft during follow-ups to a clinical trial evaluating the use of the device for treating BTAI, though none of the cases required an open surgical conversion or bypass. In past studies, the rate of thrombus within grafts ranges from 15% to 40%, the company said. Cook Medical said it has received 5 reports of graft thrombosis or occlusion during global commercial use of th...
Source: Mass Device - April 4, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Stent Grafts Stents Cook Medical Source Type: news

Firefighters Exhibit Increased Cardiovascular Impairment
Increased thrombus formation, increased platelet - monocyte binding with exposure to fire simulation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 4, 2017 Category: Cancer & Oncology Tags: Cardiology, Internal Medicine, Oncology, Journal, Source Type: news

Routine Imaging After TAVR Suggested to Catch Thrombosis
(MedPage Today) -- German data supports ' significant ' prevalence warranting routine check (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 3, 2017 Category: Cardiology Source Type: news

Overall Risk of VTE Recurrence Similar for iSVT, Proximal DVT
Isolated superficial vein thrombosis tied to increased risk of iSVT recurrence, lower risk of deep - VTE events (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 31, 2017 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news

Absorb Stent Thrombosis Again; Nonischemic HF ICDs; Triage on Blood Thinner
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 31, 2017 Category: Primary Care Source Type: news

Bioresorbable Scaffold Stent Thrombosis Again; Nonischemic HF ICDs; Triage on Blood Thinner
(MedPage Today) -- Cardiovascular Daily wraps up the top cardiology news of the week (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 31, 2017 Category: Cardiology Source Type: news

Role of imaging modalities is changing for PE diagnosis
The use of ventilation/perfusion SPECT scans to rule out pulmonary embolism...Read more on AuntMinnie.comRelated Reading: Video from ECR 2017: Dr. Martine Rémy-Jardin on pulmonary embolism Ultrasound elevates diagnosis of pulmonary embolism Triple rule-out CT offers one-stop shop for chest pain Can ultrasound for deep vein thrombosis cause a PE? Societies issue imaging guidelines for chest pain (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 31, 2017 Category: Radiology Source Type: news

Bioresorbable Vascular Scaffold: New Data Add to Concerns over Thrombosis Risk (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM New findings add to growing concerns surrounding increased rates of device thrombosis in patients who receive bioresorbable vascular scaffolds during percutaneous coronary … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 30, 2017 Category: Primary Care Source Type: news

Absorb ' s Thrombosis Troubles Persist in All-Comers Trial (CME/CE)
(MedPage Today) -- And this time, implantation technique cannot be blamed (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 29, 2017 Category: Cardiology Source Type: news

Statins new: Anti-cholesterol drugs 'could combat deep vein thrombosis'
NEW evidence has emerged that widely prescribed anti-cholesterol drugs can prevent blood clots. (Source: Daily Express - Health)
Source: Daily Express - Health - March 28, 2017 Category: Consumer Health News Source Type: news

Statins breakthrough: Cholesterol-lowering drugs 'could combat deep vein thrombosis'
STATINS, the widely prescribed drugs which lower cholesterol, can prevent blood clots, scientists have revealed. (Source: Daily Express - Health)
Source: Daily Express - Health - March 28, 2017 Category: Consumer Health News Source Type: news

Managing Thrombosis in Cancer Patients
This video reviews recommendations for the prevention and management of thrombosis in patients with cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 28, 2017 Category: Cancer & Oncology Authors: Michael Streiff, MD Source Type: news

Can a metal tube in your leg stop blood clots coming back?
Due to deep vein thrombosis (DVT), tens of thousands have to take drugs for life to escape the pain. Katalin Portik-Szabo, a nanny from London, became one of the first to try the new surgery. (Source: the Mail online | Health)
Source: the Mail online | Health - March 27, 2017 Category: Consumer Health News Source Type: news

Long - Term Thrombolytic Tx No Benefit in Intermediate - Risk PE
Findings at three years for tenecteplase vs placebo in patients with intermediate - risk pulmonary embolism (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 27, 2017 Category: Respiratory Medicine Tags: Cardiology, Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Mar 24 Cardiology News Mar 24 Cardiology News
2017 American College of Cardiology (ACC) sessions in review: PCSK9 inhibitors, bioresorbable stents, CTO-PCI procedures, subclinical leaflet thrombosis in tissue aortic valves, and NOACs feature.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 24, 2017 Category: Cardiology Tags: Cardiology News Source Type: news

Bayer's Rivaroxaban demonstrated superior protection against recurrent venous thromboembolism compared with Aspirin in EINSTEIN CHOICE study
Bayer AG and its development partner Janssen Pharmaceuticals, Inc. have announced results from the EINSTEIN CHOICE study, which demonstrated that both 10 mg and 20 mg once-daily dosages of its oral Factor Xa inhibitor rivaroxaban (Xarelto®) significantly reduced the risk of recurrent venous thromboembolism (VTE) compared with aspirin 100 mg once daily (acetylsalicylic acid, ASA) in patients who had previously completed 6 to 12 months of anticoagulation therapy for pulmonary embolism (PE) or symptomatic deep vein thrombosis (DVT). (Source: World Pharma News)
Source: World Pharma News - March 23, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Clot or bleeding?
(University of Helsinki) Because major surgery increases the risk of venous thrombosis, patients are often treated with anticoagulant medications to prevent thrombosis after surgery. Anticoagulant prophylaxis, however, increases the risk of severe bleeding. The international research group has now studied the risk of thrombosis and severe hemorrhage after urological cancer operations and other forms of urological surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 23, 2017 Category: Cancer & Oncology Source Type: news

Small Clots in Bioprosthetic Valves Should Slow TAVR Train Small Clots in Bioprosthetic Valves Should Slow TAVR Train
Dr John Mandrola summarizes the findings of a study of the RESOLVE and SAVORY registries on subclinical thrombosis in surgical and transcatheter valve replacement.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2017 Category: Cardiology Tags: Cardiology Expert Column Source Type: news

Risks of Thrombosis, Bleeding Vary by Procedure in Urological Noncancer Surgery Risks of Thrombosis, Bleeding Vary by Procedure in Urological Noncancer Surgery
Different types of urological noncancer surgery carry different risks of thrombosis and bleeding, suggesting a range of appropriate prophylaxis practices, according to a systematic review and meta-analysis.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 22, 2017 Category: Surgery Tags: Emergency Medicine News Source Type: news

Higher Leaflet Thrombosis Risk With TAVR, DAPT Not Protective Higher Leaflet Thrombosis Risk With TAVR, DAPT Not Protective
Data from two studies help clarify its true rate in transcatheter vs surgical valves, but leave open who should be screened and, if dual antiplatelets aren ' t protective, the type and timing of anticoagulation.Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 21, 2017 Category: Cardiology Tags: Cardiology News Source Type: news

ACC: LAAO Tied to Reduction in Thromboembolism (CME/CE)
(MedPage Today) -- Afib patients saw other benefits from add-on surgical procedure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 20, 2017 Category: Cardiology Source Type: news

ACC: Watch Out for Leaflet Thrombosis on Bioprosthetic Aortic Valves (CME/CE)
(MedPage Today) -- Anticoagulation was effective prevention, treatment (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - March 20, 2017 Category: Urology & Nephrology Source Type: news

CT scans reveal reduced leaflet motion after aortic valve replacement
About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood clots around the valve leaflets (known as subclinical leaflet thrombosis) that reduced the motion of the valves, according to an observational study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 20, 2017 Category: Science Source Type: news

Closing left atrial appendage reduces stroke risk from AFib
For patients with atrial fibrillation (AFib), a common heart rhythm disorder, closing the area of the heart known as the left atrial appendage as an add-on procedure during cardiac surgery was associated with a 40 percent reduction in the risk of thromboembolism (a condition when a blood clot forms and blocks an artery, which can cause a stroke or other complications) according to an observational study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 20, 2017 Category: Science Source Type: news

ACC 2017: FDA warns on Abbott ’ s Absorb
The Absorb bioresorbable stent made by Abbott (NYSE:ABT) confers a higher risk of serious adverse events at 2 years compared with the company’s Xience drug-eluting stent, according to new data from a study that prompted the FDA to warn physicians on the risk. But the picture is clouded by new guidelines indicating the proper blood vessel size and implantation technique; some 19% of patients in the 2008-subject trial were implanted in arteries that are now deemed too small for the device. Excluding those patients, the difference between the 2 stents was not statistically significant, according to the study. “T...
Source: Mass Device - March 20, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Stents Wall Street Beat Abbott Source Type: news

Temple-led team: Sex-based differences in utilization & outcomes for CDT in DVT patients
(Temple University Health System) One treatment for deep vein thrombosis (DVT) is a procedure called catheter-directed thrombolysis (CDT). CDT has become more commonly used in the US since research showed it reduced the incidence of post-thrombotic syndrome.A team led by Temple University Hospital's Riyaz Bashir, MD, sought to identify and describe sex-based differences in utilization and safety outcomes of CDT for treatment of DVT in the U.S. The team found sex-based differences in both utilization and safety outcomes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2017 Category: Global & Universal Source Type: news

News from ACC 2017: Rivaroxaban vs. Aspirin to Prevent Recurrent VTE / Evolocumab ' s Clinical Outcomes / More... (FREE)
By the Editors The American College of Cardiology ' s annual meeting brought forth a flood of heart-related medical news this weekend. Here ' s a quick look at the studies we thought you ' d be most interested in:Rivaroxaban vs. Aspirin for Recurrent VTE: Nearly 3400 adults with venous thromboembolism who ' d completed 6 –12 months of anticoagulation were randomized to daily rivaroxaban (20 or 10 mg) or aspirin (100 mg). At 1 year, rates of symptomatic recurrent VTE were significantly lower with rivaroxaban (1.5% and 1.2%) than with aspirin (4.4%), with no differences in major bleeding across the groups. Dr. Allan Brett...
Source: Physician's First Watch current issue - March 19, 2017 Category: Primary Care Source Type: news

New Phase 3 Study Finds XARELTO ® to Be Superior to Aspirin for Long-Term Prevention of Recurrent Blood Clots Without Observing any Significant Increase in Major Bleeding in Patients with Venous Thromboembolism
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 18, 2017 Category: Pharmaceuticals Source Type: news

FDA Issues Warning for Absorb Stent
(MedPage Today) -- Higher risk of stent thrombosis and MI under investigation (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 18, 2017 Category: American Health Source Type: news

FDA Probing Absorb Stent
(MedPage Today) -- Higher risk of stent thrombosis and MI under investigation (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 18, 2017 Category: American Health Source Type: news

EINSTEIN CHOICE: Rivaroxaban Beats Aspirin for VTE Recurrence EINSTEIN CHOICE: Rivaroxaban Beats Aspirin for VTE Recurrence
Extended therapy with rivaroxaban at either 20 mg or 10 mg was more effective than aspirin at preventing recurrent venous thromboembolism without an increased risk of bleeding.Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 18, 2017 Category: Cardiology Tags: Cardiology News Source Type: news